Financial Performance - The company's operating revenue for the third quarter was CNY 151.06 million, a decrease of 34.63% compared to the same period last year[5] - The net profit attributable to shareholders was CNY -926.72 million, reflecting a decline of 130.17% year-on-year[5] - The net cash flow from operating activities decreased by 138.43% to CNY -80.82 million, primarily due to reduced sales receipts[12] - Total operating revenue for the current period was CNY 647,287,705.63, a decrease of 16.1% compared to CNY 771,707,421.15 in the previous period[24] - Net profit for the current period was CNY 42,581,204.94, a decrease of 11.0% from CNY 47,882,035.92 in the previous period[25] - Operating cash flow for the current period is -80,815,697.32 CNY, a decrease from 210,294,883.27 CNY in the previous period, indicating a significant decline in operational performance[26] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1.32 billion, down 8.49% from the beginning of the year[5] - The total assets decreased to CNY 1,323,934,517.72 from CNY 1,446,715,474.87, reflecting a decline of 8.5%[23] - Total liabilities decreased to CNY 567,117,685.67 from CNY 706,898,011.15, a reduction of 19.7%[23] - The company's cash and cash equivalents decreased from 310,022,521.29 CNY to 178,646,043.67 CNY, a decline of approximately 42.4%[21] Shareholder Information - The company's total equity attributable to shareholders increased by 2.90% to CNY 690.06 million[5] - The total number of common stock shareholders at the end of the reporting period is 27,149[15] - Gansu Pharmaceutical Investment Group holds 29.93% of shares, totaling 90,785,250 shares[15] - The total number of restricted shares at the end of the period is 1,293,512 shares, after 10,875 shares were released from restriction[18] - The company has not reported any changes in the top 10 shareholders due to securities lending activities[16] Cash Flow and Financing - The company reported a 91.40% increase in net cash flow from financing activities, attributed to compensation received and increased loans[13] - Total cash inflow from financing activities is 65,774,162.99 CNY, compared to 27,258,789.48 CNY in the previous period, showing an increase in financing efforts[27] - The company reported a net cash flow from financing activities of -11,132,357.71 CNY, an improvement from -129,508,773.79 CNY in the previous period, indicating better management of financing[27] Expenses and Costs - The company's long-term expenses increased by 101.63% due to rising costs related to cafeteria and laboratory renovations[9] - The financial expenses decreased by 57.15% as a result of loan repayments and reduced interest expenses[12] - Total operating costs for the current period were CNY 590,299,154.53, down 16.4% from CNY 706,276,206.26 in the previous period[24] - Cash outflow from operating activities totaled 882,294,800.49 CNY, up from 763,293,545.30 CNY in the previous period, indicating increased operational costs[26] Investments and Assets - The company’s non-current assets include fixed assets valued at 480,556,245.88 CNY, a slight decrease from 488,659,976.91 CNY[21] - The company’s intangible assets increased from 63,064,636.04 CNY to 76,493,385.92 CNY, an increase of approximately 21.4%[21] - Cash inflow from investment activities was 800,500.00 CNY, an increase from 600,000.00 CNY in the previous period, suggesting improved investment returns[26] - Cash outflow from investment activities decreased to 40,228,922.59 CNY from 55,405,311.68 CNY, indicating reduced capital expenditures[26] - The company received 2,800,000.00 CNY from investment, significantly higher than 750,000.00 CNY in the previous period, reflecting increased investor confidence[27] Future Outlook and Standards - The company plans to implement new accounting standards starting in 2025, which may impact future financial reporting[28] - The company did not undergo an audit for the third quarter financial report, which may affect investor confidence in the reported figures[28]

Core Insights - The company Longshen Rongfa (300534) reported that as of October 20, 2025, the number of shareholders is 27,796 [1] Group 1 - The company is actively engaging with investors through interactive platforms [1]

Group 1 - The company announced that independent director Li Zongyi has submitted his resignation due to personal work reasons [2] - Li Zongyi will no longer hold any positions within the company after his resignation [2]

Group 1 - The company Longshen Rongfa announced on October 17 that its 22nd meeting of the fifth board of directors was held via communication voting [1] - The meeting reviewed the proposal regarding the convening of the fifth temporary shareholders' meeting in 2025 [1] Group 2 - Lin Yuan responded firmly to market losses during the bull market, stating "I am still here!" and emphasized that he will continue to invest [1] - Lin Yuan maintains that liquor is a "happy demand" and expressed concerns about technology stocks, indicating they cause him sleepless nights [1]

Core Points - Independent director Li Zongyi has applied to resign from his position and all related committee roles due to personal work reasons [1] - Li Zongyi's resignation will take effect after the election of a new independent director at the company's shareholders' meeting [1] - During the interim period, Li Zongyi will continue to fulfill his responsibilities [1] - The company has nominated Fang Wenbin as the candidate for the new independent director, pending approval from the Shenzhen Stock Exchange before submission to the shareholders' meeting [1]

证券代码：300534 证券简称：陇神戎发 公告编号：2025-072 甘肃陇神戎发药业股份有限公司 独立董事候选人声明与承诺 声明人方文彬先生作为甘肃陇神戎发药业股份有限公司第五届董事会独 立董事候选人，已充分了解并同意由提名人甘肃陇神戎发药业股份有限公司第 五届董事会提名为甘肃陇神戎发药业股份有限公司（以下简称该公司）第五届 董事会独立董事候选人。现公开声明和保证，本人与该公司之间不存在任何影 响本人独立性的关系，且符合相关法律、行政法规、部门规章、规范性文件和 深圳证券交易所业务规则对独立董事候选人任职资格及独立性的要求，具体声 明并承诺如下事项： 一、本人已经通过甘肃陇神戎发药业股份有限公司第五届董事会提名委员 会资格审查，提名人与本人不存在利害关系或者其他可能影响独立履职情形的 密切关系。 是 □ 否 如否，请详细说明：______________________________ 二、本人不存在《中华人民共和国公司法》第一百七十八条等规定不得担 任公司董事的情形。 是 □ 否 如否，请详细说明：______________________________ 三、本人符合中国证监会《上市公司独立董事管理 ...

二、被提名人不存在《中华人民共和国公司法》第一百七十八条等规定不 得担任公司董事的情形。 甘肃陇神戎发药业股份有限公司 独立董事提名人声明与承诺 是 □ 否 证券代码：300534 证券简称：陇神戎发 公告编号：2025-071 提名人甘肃陇神戎发药业股份有限公司第五届董事会现就提名方文彬先 生为甘肃陇神戎发药业股份有限公司第五届董事会独立董事候选人发表公开 声明。被提名人已书面同意作为甘肃陇神戎发药业股份有限公司第五届董事会 独立董事候选人。本次提名是在充分了解被提名人职业、学历、职称、详细的 工作经历、全部兼职、有无重大失信等不良记录等情况后作出的，本提名人认 为被提名人符合相关法律、行政法规、部门规章、规范性文件和深圳证券交易 所业务规则对独立董事候选人任职资格及独立性的要求，具体声明并承诺如下 事项： 一、被提名人已经通过甘肃陇神戎发药业股份有限公司第五届董事会提名 委员会资格审查，提名人与被提名人不存在利害关系或者其他可能影响独立履 职情形的密切关系。 是 □ 否 如否，请详细说明：______________________________ 如否，请详细说明：___________________ ...

证券代码：300534 证券简称：陇神戎发 公告编号：2025-069 甘肃陇神戎发药业股份有限公司 关于独立董事辞职暨提名独立董事候选人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、关于公司独立董事辞职的情况 甘肃陇神戎发药业股份有限公司（以下简称"公司"）董事会于近日收到公 司独立董事李宗义先生的书面辞职报告，因个人工作原因，李宗义先生申请辞去 公司独立董事职务及董事会审计委员会主任委员、薪酬与考核委员会委员职务， 其辞职后不再担任公司任何职务，李宗义先生原定任期为2024年1月3日至2027 年 1 月 2 日。 鉴于李宗义先生的辞职将导致公司董事会及相关专门委员会中独立董事所 占比例不符合相关法律法规、规范性文件和《公司章程》的规定，且公司独立董 事中缺少一名会计专业人士，根据《公司法》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》等法律法规及《公司章程》的有关 规定，李宗义先生的辞职将在公司股东会选举产生新任独立董事填补其空缺后生 效，在此期间，李宗义先生将继续履行独立董事及董事会审计委员会主任委员、 薪酬 ...

证券代码：300534 证券简称：陇神戎发 公告编号：2025-070 甘肃陇神戎发药业股份有限公司 关于召开2025年第五次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1.股东会届次：2025年第五次临时股东会 2.股东会的召集人：董事会 3.本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所 创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号—创业板上 市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》的 有关规定。 4.会议时间： （1）现场会议时间：2025年11月4日14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025年11月4日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为2025年11月4日9:15至15:00的任意时间。 5.会议的召开方式：本次股东会采用现场表决与网络投票相结合的方式召开， 公司股东只能选择现场投票（现场投票可以委托代理人代为投票）和 ...

证券代码：300534 证券简称：陇神戎发 公告编号：2025-068 甘肃陇神戎发药业股份有限公司 第五届董事会第二十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 甘肃陇神戎发药业股份有限公司（以下简称"公司"）第五届董事会第二十 二次会议于 2025 年 10 月 17 日以通讯表决方式召开，本次会议以豁免通知时限 形式于 2025 年 10 月 16 日以电子邮件等形式通知全体董事。本次会议由公司董 事长康永红先生主持，应出席会议董事 9 人，实际出席会议董事 9 人，公司高级 管理人员列席了会议。本次会议的召集、召开符合《公司法》等有关法律、行政 法规、部门规章和《公司章程》的相关规定，合法有效。 二、董事会会议审议情况 会议审议并通过了如下议案： 1.审议通过《关于补选公司第五届董事会独立董事的议案》 表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案尚需提交公司 2025 年第五次临时股东会审议。 2.审议通过《关于召开 2025 年第五次临时股东会的议案》 经审议，董事会同意公司根据经营需要于 ...